¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"lethal mutation model"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • chromosome mutation
    ¿°»öüµ¹¿¬º¯ÀÌ
  • drift mutation
    ¿¬¼Óº¯ÀÌ
  • dominant mutation
    ¿ì¼ºµ¹¿¬º¯ÀÌ
  • extragenic suppressor mutation
    À¯ÀüÀڿܹßÇö¾ïÁ¦µ¹¿¬º¯ÀÌ
  • forward mutation
    ¾ÕÂʵ¹¿¬º¯ÀÌ, ÀüÇâµ¹¿¬º¯ÀÌ
  • frameshift mutation
    ƲÀ̵¿µ¹¿¬º¯ÀÌ
  • genetic mutation
    À¯Àüµ¹¿¬º¯ÀÌ
  • genomic mutation
    À¯Àüüµ¹¿¬º¯ÀÌ
  • induced mutation
    À¯¹ßµ¹¿¬º¯ÀÌ
  • loss-of-function mutation
    ±â´É¼Ò½Çµ¹¿¬º¯ÀÌ
  • missense mutation
    °ú¿Àµ¹¿¬º¯ÀÌ, ¹Ì½º¼¾½ºµ¹¿¬º¯ÀÌ
  • mutation
    µ¹¿¬º¯ÀÌ
  • mutation genetics
    º¯ÀÌÀ¯ÀüÇÐ
  • mutation rate
    µ¹¿¬º¯ÀÌÀ²
  • natural mutation
    ÀÚ¿¬µ¹¿¬º¯ÀÌ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • dominant mutation
    ¿ì¼ºµ¹¿¬º¯ÀÌ
  • drift mutation
    ¿¬¼Óº¯ÀÌ
  • mutation detection
    µ¹¿¬º¯À̰ËÃâ
  • extragenic suppressor mutation
    À¯ÀüÀڿܹßÇö¾ïÁ¦µ¹¿¬º¯ÀÌ
  • forward mutation
    ÀüÇâµ¹¿¬º¯ÀÌ
  • frequency mutation
    µ¹¿¬º¯À̺óµµ
  • genetic mutation
    À¯Àüµ¹¿¬º¯ÀÌ
  • genomic mutation
    À¯ÀüÀÚµ¹¿¬º¯ÀÌ, À¯Àüüµ¹¿¬º¯ÀÌ
  • mutation genetics
    º¯ÀÌÀ¯ÀüÇÐ
  • host range mutation
    ¼÷ÁÖ¹üÀ§º¯ÀÌ, ¼÷ÁÖ¿ªº¯ÀÌ
  • induced mutation
    À¯¹ßµ¹¿¬º¯ÀÌ
  • loss mutation
    »ó½Çµ¹¿¬º¯ÀÌ
  • mutation
    µ¹¿¬º¯ÀÌ
  • missense mutation
    °ú¿Àµ¹¿¬º¯ÀÌ
  • multiple allelic mutation
    ¹µ¸Â¼¶µ¹¿¬º¯ÀÌ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • induced mutation
    À¯¹ßµ¹¿¬º¯ÀÌ
  • induced mutation
    À¯¹ß¼º µ¹¿¬º¯ÀÌ.
  • plaque morphology mutation
    ÇöóÅ© ÇüÅ µ¹¿¬º¯ÀÌ
  • plaque-type mutation
    ÇöóÅ©Çü µ¹¿¬º¯ÀÌ
  • point mutation
    Á¡ µ¹¿¬º¯ÀÌ
  • point mutation
    Á¡µ¹¿¬º¯ÀÌ
  • population mutation
    Áý´Ü±ºµ¹¿¬º¯ÀÌ(¡­ÔÍæÔܨì¶).
  • recessive mutation
    ¿­¼ºµ¹¿¬º¯ÀÌ(æëàõÔÍæÔܨì¶).
  • recessive mutation
    ¿­¼ºµ¹¿¬º¯ÀÌ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lethal midline granuloma
    ¾Ç¼ºÁß½É(¼º)À°¾ÆÁ¾
  • lethal midline granuloma
    Ä¡»ç¼º Á߽ɼ± À°¾ÆÁ¾
  • lethal midline granuloma
    Ä¡»ç¼ºÁ߽ɼ±À°¾ÆÁ¾(öÈÞÝàõñéãýàÊë¿ä´ðþ)
  • lethal mutant, conditional
    Á¶°ÇÄ¡»ç µ¹¿¬º¯ÀÌÁÖ
  • lethal titer test
    Ä¡»çÀû Á¤·®½ÃÇè
  • lethal toxin
    Ä¡»çµ¶¼Ò(¡­Ô¸áÈ).
  • lethal toxin
    Ä¡»çµ¶¼Ò(ÊÙËÄËÛ).
  • mean lethal dose =LD50
    50% Ä¡»ç·® (¡­öÈÞÝåÖ).
  • mean lethal dose, Do
    Æò±ÕÄ¡»ç¼±·®
  • median lethal dose =LD50
    50% Ä¡»ç·®(¡­öÈÞÝåÖ), Æò±ÕÄ¡»ç·®.
  • median lethal dose, MLD
    Áß¾ÓÄ¡»ç¼±·®
  • minimal lethal dose
    ÃÖ¼ÒÄ¡»ç·®(õÌá´öÈÞÝåÖ).
  • minimal lethal dose
    ÃÖ¼ÒÄ¡»ç·®(̧ËÛ̬Ë×Ëâ).
  • minimal lethal dose
    ÃÖ¼ÒÄ¡»ç·®(õÌá³öÈÞÝåÖ).
  • minimum lethal dose (MLD)
    ÃÖ¼ÒÄ¡»ç·®
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • constitutive mutation
    ±¸¼ºº¯ÀÌ(ϰà÷ܨì¶)
  • copy-error mutation
    º¹»ç¿À·ù º¯ÀÌ(ÜÜÞÐè¦×½Ü¨ì¶)
  • down promoter mutation
    ÇÏÇâÃËÁøÀÚ º¯ÀÌ(ù»ú¾õµòäí­Ü¨ì¶) (ÔÒ) promoter down mutation
  • end-point mutation
    Á¾¸»Á¡ º¯ÀÌ (ðûØÇïÇܨì¶)
  • forward mutation
    ³ªÅ¸³² º¯ÀÌ(ܨì¶)
  • frameshift mutation
    ƲÀ̵¿(ì¹ÔÑ) º¯ÀÌ(ܨì¶)
  • germinal mutation
    ¹è¼¼Æ÷ º¯ÀÌ(ÛÏá¬øàܨì¶)
  • induced mutation
    À¯µµº¯ÀÌ(ë¯Óôܨì¶)
  • intergenic suppressor mutation
    À¯ÀüÀÚ°£ ¾ï¾ÐÀÚº¯ÀÌ(ë¶îîí­Êàåääâí­Ü¨ì¶)
  • intragenic suppression mutation
    À¯ÀüÀÚ³» ¾ï¾Ðº¯ÀÌ(ë¶îîí­Ò®åääâܨì¶)
  • isocoding mutation
    ¾ÆÀ̼ÒÄÚµå º¯ÀÌ(ܨì¶)
  • Jimpy mutation
    ÁüÇÇ º¯ÀÌ(ܨì¶)
  • missense mutation
    ¿ÀÀκ¯ÀÌ(è¦ìãܨì¶)
  • mutation
    º¯ÀÌ(ܨì¶)
  • mutation distance
    º¯ÀÌ(ܨì¶)°Å¸®
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CPK cell population kinetic [model]; creatine phosphokinase
GHPM general health policy model
GLIM generalized linear interactive model
GLM general linear model
HBM health belief model; hypertonic buffered medium
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MCR mutation cluster region
M(f) mutation frequency
Tfm testicular feminization mutation
CIGMA Continuous Infusion of Glucose with Model Assessment
FEM finite element model
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • deletion model
    °á½Ç ¸ðµ¨
    µ¹¿¬º¯ÀÌÀÇ ÇϳªÀ̸ç À¯Àü ¹°ÁúÀÇ ÀϺκÐÀÌ °á¿©µÇ¾î ÀÖ´Â °Í. ¸é¿ª À¯ÀüÇп¡¼­´Â ¸é¿ª ±Û·ÎºÎ¸°ÀÇ H¼â À¯ÀüÀÚ±ºÀ» ÆÇµ¶ÇÏ´Â ±â±¸·Î¼­ÀÇ ´ë¸³ À¯ÀüÀÚ °á½Ç ¸ðµ¨ÀÌ À¯¸íÇÏ´Ù.
  • in the ear model
    ±Í¼ÓÇü
  • integrating conceptual model
    ÅëÇÕ °³³ä ¸ðÇü
  • model
    ¸ðµ¨, º»º¸±â, ¸ðÇü, Ç¥ÁØÇü
    Áø´ÜÇÐ ¶Ç´Â ÇØºÎÇÐ ¿¬±¸¿ëÀÇ ¸ðÇü°ú °°ÀÌ ´Ù¸¥ ¹°°ÇÀ» Ç¥ÇöÇÏ´Â °Í Ä¡°úÇп¡¼­ÀÇ ÁÖÇü Ç¥º».
  • model base
    ¸ðÇü Àú¸é
    ¸ðÇüÀÇ ¹Ø¸é.
  • model mounting
    ¸ðÇü ºÎÂø
    ÀÛ¾÷ ¸ðÇü°ú ´ëÇÕ Ä¡¿­ ¸ðÇüÀ» ±³Çձ⿡ ºÎÂø½ÃŰ´Â °úÁ¤.
  • model population
    ¸ðÇü Àα¸
  • MSV model

    MTD (ÃÖ´ë ³»¿ë·®

  • nuclear model
    ÇÙ ¸ðÇü
  • plaster matrix

    plaster model

    ¼®°í ¸ðÇü, ±é½ºÇü
  • psychodynamic experiential model
    Á¤½Å ¿ªµ¿Àû °æÇè ¸ðµ¨
  • symmetry model
    ´ëĪÇü, ´ëμ³
  • wave model
    ÆÄÇü
  • working model for bridgework
    °¡°ø ÀÇÄ¡ ÀÛ¾÷ ¸ðÇü
  • amber mutation
    ¾Ïº£¸£ µ¹¿¬º¯ÀÌ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
lethal dose <pharmacology> The amount, or dosage, of a toxin necessary to cause death.
(16 Mar 1998)
lethal dose 50 <pharmacology> The amount, or dosage, of a toxin necessary to kill 50% of the experimental subjects.
(16 Mar 1998)
lethal dwarfism Dwarfism leading to intrauterine or neonatal death.
(05 Mar 2000)
lethal equivalent A combination of selective effects that on average have the same impact on the composition of the gene pool as one death; e.g., two carriers at 50% risk of dying would be the lethal equivalent of one carrier at 100% risk, in the population genetics of recessive traits lethal equivalent is expressed as twice the sum of the expected number of deaths ascribable to the genetic load.
Expression used of the genetic load of recessive genes in heterozygous state that if in homozygous state would cause death or carry a risk of death. The expected number of deaths from all such genes is expressed in lethal equivalent.
(05 Mar 2000)
lethal factor A disorder that prevents effective reproduction by those affected; e.g., Klinefelter syndrome.
(05 Mar 2000)
lethal gene A gene that produces a genotype that leads to death of the organism before reproduction is possible or that precludes reproduction; for a recessive gene the homozygous or hemizygous state is lethal.
(05 Mar 2000)
lethal midline granuloma Destruction of the nasal septum, hard palate, lateral nasal walls, paranasal sinuses, skin of the face, orbit and nasopharynx by an inflammatory infiltrate with atypical lymphocytic and histiocytic cells; presumably a form of lymphoma in most cases.
An obsolete term for polymorphic reticulosis.
Synonym: granuloma gangrenescens, malignant granuloma, midline malignant reticulosis granuloma.
(05 Mar 2000)
Adair-Koshland-Nemethy-Filmer model <biochemistry, chemistry> A model to explain the allosteric form of cooperativity; in this model, in the absence of ligands, the protein exists in only one conformation; upon binding, the ligand induces a conformational change that may be transmitted to other subunits.
Synonym: Adair-Koshland-Nemethy-Filmer model, induced fit model.
(05 Mar 2000)
additive model A model in which the combined effect of several factors is the sum of the effects that would be produced by each of the factors in the absence of the others.
(05 Mar 2000)
age-structured model <epidemiology> A mathematical model which take into consideration the division of the host population into different age classes. Such models can used to consider the consequences of such factors as age-dependent infection, morbidity or mortality rates or of age-specific vaccination schedules.
(05 Dec 1998)
animal model Study in a population of laboratory animals that uses conditions of animals analogous to conditions of humans to simulate processes comparable to those that occur in human populations.
(05 Mar 2000)
Bingham model A model representing the flow behaviour of a Bingham plastic, in the idealised case.
(05 Mar 2000)
biomedical model A conceptual model of illness that excludes psychological and social factors and includes only biological factors in an attempt to understand a person's medical illness or disorder.
(05 Mar 2000)
biopsychosocial model A conceptual model that assumes that psychological and social factors must also be included along with the biological in understanding a person's medical illness or disorder.
(05 Mar 2000)
genetic model A formalised conjecture about the behaviour of a heritable structure in which the component terms are intended to have literal interpretation as standard structures of empirical genetics.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • macroeconomic model
    °Å½ÃÀû °æÁ¦ ¸ðµ¨
  • model
    ¸ðÇü;¿øÇü;º»;¼³°èµµ;¸ðµ¨;¸¶³×Ų;¸ð¹ü;¸ð¹üÀûÀÎ;¸ðÇüÀÇ;¸ð¾çÀ» ¸¶µé´Ù(Á¡Åä µûÀ§¸¦ ¾î¶² ÇüÀ¸·Î)¶ß´Ù;¼³°èÇÏ´Ù;...À» º»¶ß´Ù;model school ½Ã¹ý Çб³)
  • model builder
    °æÁ¦ ¸ðµ¨ÀÇ ÀÛ¼ºÀÚ
  • model building
    ¸ðµ¨ ±¸¼º
  • model(l)er
    ¸ðÇü(¼Ò»ó)À» ¸¸µå´Â »ç¶÷
  • role model
    ¿ªÇÒ ¸ðµ¨
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á